CytomX Therapeutics (NASDAQ:CTMX) Now Covered by StockNews.com

StockNews.com began coverage on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. Piper Sandler began coverage on shares of CytomX Therapeutics in a research note on Monday. They set an “overweight” rating and a $2.50 price target for the company. Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of CytomX Therapeutics in a research report on Friday, March 7th. Finally, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.77.

CytomX Therapeutics Trading Up 4.2 %

CTMX stock opened at $0.63 on Tuesday. The stock has a market cap of $50.58 million, a P/E ratio of 3.71 and a beta of 1.34. The stock’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $0.90. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. As a group, analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

A number of large investors have recently made changes to their positions in the stock. Miller Financial Services LLC purchased a new stake in CytomX Therapeutics during the 4th quarter worth about $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at about $31,000. Algert Global LLC purchased a new stake in shares of CytomX Therapeutics in the fourth quarter worth about $35,000. Velan Capital Investment Management LP bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Aspire Growth Partners LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter valued at approximately $42,000. 67.77% of the stock is owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.